Preclinical Prediction of Resistance and Optimization of Sequential Therapy for ALK-positive Lung Cancer Using Next-generation ALK Inhibitors
Yuki Takei, Hirotaka Kuroiwa, Chisaki Arai, Yuta Doi, Kentaro Semba
This study predicts resistance mutations to next-generation ALK inhibitors and evaluates sequential therapy strategies for ALK-positive lung cancer.
bioRxiv · May 26, 2025 · PreprintCancer Biology